We’re excited to welcome Michael Nall as CEO and Board Director of Exai Bio. Mike brings decades of diagnostics and commercial expertise that will be instrumental as we scale our RNA- and AI-based liquid biopsy platform and early detection efforts.
We’re also proud to announce the addition of three distinguished leaders to our Board of Directors - Steve Kafka, General Partner at S32, Dusan Perovic, Partner at Two Sigma Ventures and Emir Sandhu, MD, Managing Director at Blue Venture Fund. Their collective insight and leadership will be invaluable as we advance commercial partnerships and expand our impact across cancer care.
Hani Goodarzi, PhD, is the UCSF inventor and founder.